胰高血糖素样肽-1受体激动剂的生理和心理作用。

Q3 Nursing

Nursing Pub Date : 2025-09-01 Epub Date: 2025-08-25 DOI:10.1097/NSG.0000000000000223

Sarah A Browne-Bradwisch, Erin Murphy Smith, Catherine Wilson-Mooney, Courtney Donahue-Stathis

{"title":"胰高血糖素样肽-1受体激动剂的生理和心理作用。","authors":"Sarah A Browne-Bradwisch, Erin Murphy Smith, Catherine Wilson-Mooney, Courtney Donahue-Stathis","doi":"10.1097/NSG.0000000000000223","DOIUrl":null,"url":null,"abstract":"Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were approved by the FDA to treat type 2 diabetes (T2D) and to reduce the risk of major cardiovascular events in patients with T2D and known heart disease. With an alarming rise in T2D prevalence as well as its associated complications, the need for adequate treatment strategies for this chronic disease has never been higher. GLP-1 RAs have beneficial effects in treating T2D. This article discusses updates on the safety and effectiveness of GLP-1 RAs for obesity and many related conditions.","PeriodicalId":35641,"journal":{"name":"Nursing","volume":"55 9","pages":"48-54"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The physiologic and psychologic effects of glucagon-like peptide-1 receptor agonists.\",\"authors\":\"Sarah A Browne-Bradwisch, Erin Murphy Smith, Catherine Wilson-Mooney, Courtney Donahue-Stathis\",\"doi\":\"10.1097/NSG.0000000000000223\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were approved by the FDA to treat type 2 diabetes (T2D) and to reduce the risk of major cardiovascular events in patients with T2D and known heart disease. With an alarming rise in T2D prevalence as well as its associated complications, the need for adequate treatment strategies for this chronic disease has never been higher. GLP-1 RAs have beneficial effects in treating T2D. This article discusses updates on the safety and effectiveness of GLP-1 RAs for obesity and many related conditions.\",\"PeriodicalId\":35641,\"journal\":{\"name\":\"Nursing\",\"volume\":\"55 9\",\"pages\":\"48-54\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nursing\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/NSG.0000000000000223\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"Nursing\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nursing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/NSG.0000000000000223","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Nursing","Score":null,"Total":0}

引用次数: 0

摘要

胰高血糖素样肽-1受体激动剂（GLP-1 RAs）已被FDA批准用于治疗2型糖尿病（T2D），并降低T2D和已知心脏病患者发生主要心血管事件的风险。随着T2D患病率及其相关并发症的惊人上升，对这种慢性疾病的适当治疗策略的需求从未如此高涨。GLP-1 RAs在治疗T2D中有有益作用。本文讨论了GLP-1 RAs治疗肥胖和许多相关疾病的安全性和有效性的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The physiologic and psychologic effects of glucagon-like peptide-1 receptor agonists.

Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were approved by the FDA to treat type 2 diabetes (T2D) and to reduce the risk of major cardiovascular events in patients with T2D and known heart disease. With an alarming rise in T2D prevalence as well as its associated complications, the need for adequate treatment strategies for this chronic disease has never been higher. GLP-1 RAs have beneficial effects in treating T2D. This article discusses updates on the safety and effectiveness of GLP-1 RAs for obesity and many related conditions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nursing Medicine-Medicine (all)

CiteScore

0.80

自引率

0.00%

发文量

338

期刊介绍： Nursing2020 (ISSN 0360-4039; online ISSN 1538-8689) published its first issue in November 1971, under founders Gene W. Jackson and Daniel Cheney. In the intervening years, its circulation has grown to over 150,000, making it one of the largest nursing journals in the world. Published monthly, Nursing2020 is widely regarded as offering current, practical contents to its readers, and has won many editorial awards testifying to the quality of its copy and graphics. The editorial and clinical staff, a 19-member Editorial Board of distinguished clinicians and practitioners, and over 100 invited reviewers help ensure the quality of this publication.